Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Advances In™ Basal Cell Carcinoma: Exploring the Latest Advances Across the Treatment Continuum

Release Date: June 14, 2021
Expiration Date: June 14, 2022

Activity Overview

This brief online educational activity is designed to quickly bring participants up to speed on the rationale and clinical trial evidence supporting novel approaches for the management of locally advanced and basal cell carcinoma. It is presented in a multimedia format, featuring text content supplemented by video interviews with experts in the management of basal cell carcinoma.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This activity is directed toward medical oncologists, radiation oncologists, and dermatologists involved in the treatment and management of basal cell carcinoma (BCC). Fellows, nurses, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with BCC will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to

Explain the risk factors associated with recurrence in basal cell carcinoma (BCC), to inform treatment decision-making among patients with these tumors
Evaluate key efficacy and safety findings from trials evaluating immune checkpoint inhibitors (ICIs) among patients with BCC
Summarize the impact of emerging clinical data assessing ICIs in advanced/metastatic BCC within the context of evolving treatment paradigms

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible entities.

Faculty

Janice M. Mehnert, MD
Associate Director for Clinical Research
Perlmutter Cancer Center
NYU Langone Health
New York, NY

Professor of Medicine
NYU Grossman School of Medicine
New York, NY

Director, Melanoma and Cutaneous Medical Oncology
New York, NY

Disclosures: Grant/Research Support: Amgen, AstraZeneca, Bristol Myers Squibb, EMD Serono, Immunocore, Incyte Corp, MacroGenics, Merck and Co, Novartis, Polynoma, Sanofi; Consultant: Amgen, Merck Sharp & Dohme; Other: Honoraria: EMD Serono, Pfizer; Advisory Board: Array BioPharma, Bristol Myers Squibb, EMD Serono, Sanofi/Regeneron, Seagen; Trial Funded: Replimune

Ragini R. Kudchadkar, MD
Associate Professor, Department of Hematology/Oncology
Director, Melanoma and Skin Cancer Program Chair
Protocol Review and Monitoring Committee
Winship Cancer Institute
Emory University
Atlanta, GA

Disclosures: Grant/Research Support: Bristol Myers Squibb, Merck and Co, Regeneron; Consultant: Bristol Myers Squibb, Merck and Co, Pfizer, Regeneron

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.